导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.29% | 3532/4762 |
| 近一周 | -1.65% | 2442/5451 |
| 近一月 | -7.78% | 4667/5408 |
| 近一季 | 5.74% | 295/5218 |
| 近半年 | -6.72% | 3234/4907 |
| 近一年 | -16.50% | 3825/4387 |
| 近两年 | 13.62% | 2756/2950 |
| 近三年 | -10.08% | 2029/2249 |
| 成立以来 | -21.69% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.89% 2007/4961 |
-8.55% 3894/5312 |
- - |
- - |
| 2025 | 5.08% 3016/4813 |
1.69% 1570/3635 |
2.81% 1335/4076 |
9.63% 3342/4524 |
-8.33% 3902/4813 |
| 2024 | -10.35% 2339/3463 |
-9.88% 2302/2808 |
-5.81% 1801/3014 |
16.03% 1557/3129 |
-8.97% 2892/3463 |
| 2023 | -9.69% 1215/2656 |
1.37% 1581/2280 |
-7.38% 1847/2385 |
-3.45% 934/2515 |
-0.37% 205/2655 |
| 2022 | -17.41% 588/2207 |
-12.91% 666/1919 |
-0.49% 1629/2016 |
-14.16% 1038/2113 |
11.03% 156/2208 |
| 2021 | -1.25% 790/1822 |
-0.67% 380/1255 |
10.54% 454/1330 |
-12.33% 1304/1466 |
2.58% 561/1822 |
| 2020 | 42.63% 261/1250 |
9.38% 24/1028 |
29.17% 82/1067 |
3.31% 986/1164 |
-2.29% 1119/1184 |
| 2019 | 33.43% 433/1092 |
27.24% 353/739 |
-7.57% 561/788 |
8.21% 67/850 |
4.85% 772/918 |
| 2018 | -23.87% 303/834 |
- - |
-2.62% 66/631 |
-13.99% 644/660 |
-14.31% 580/682 |
| 2017 | 3.47% 427/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.89% 345/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证医药100A VS. 长安沪深300非周期A(740101) |